Evidence map›Paper›PMID 30400834›Full record

Trial reportBMC infectious diseases2018

Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI): study protocol.

Avital Hirsch, Mark A Katz, Alon Laufer Peretz, David Greenberg, Rachael Wendlandt, Yonat Shemer Avni, Gabriella Newes-Adeyi, Ilan Gofer, Maya Leventer-Roberts, Nadav Davidovitch and 15 more

2 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03331991 completednot on this map

Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel

TypeobservationalSponsorAbt AssociatesRan2016 to 2019Enrolled2,400ConditionsRespiratory Tract Disease, InfluenzaArmsinfluenza vaccine
NCT04523324 phase4completednot on this mapstarted 2019, after this paper: background citation

Randomized Comparison of the Immunogenicity of Recombinant and Egg-based Influenza Vaccines Among Healthcare Personnel in Israel

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2019 to 2022Enrolled577ConditionsInfluenzaArmsFlublok™ Quadrivalent by Sanofi, Inc., VaxigripTetra™ by Sanofi, Inc.
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Trial
  2. Article
  3. Incidence of laboratory-confirmed influenza and RSV and associated presenteeism and absenteeism among healthcare personnel, Israel, influenza seasons 2016 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 3 countries.

Avital HirschChief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel. avitalhi@clalit.org.il.
Mark A KatzChief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel.
Alon Laufer PeretzRabin Medical Center, Occupational Medicine Department, Petah Tikva, Israel.
David GreenbergPediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.
Rachael WendlandtAbt Associates, Inc, Atlanta, GA, USA.
Yonat Shemer AvniClinical Virology, Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.
Gabriella Newes-AdeyiAbt Associates, Inc, Atlanta, GA, USA.
Ilan GoferChief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel.
Maya Leventer-RobertsChief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel.
Nadav DavidovitchDepartment of Health Systems Management, School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Anat RosenthalDepartment of Health Systems Management, School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Rachel Gur-ArieDepartment of Health Systems Management, School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Tomer HertzDepartment of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Aharona Glatman-FreedmanIsrael Center for Disease Control, Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Arnold S MontoDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Eduardo Azziz-BaumgartnerInfluenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Jill Morris FerdinandsInfluenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Emily Toth MartinDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Ryan E MaloshDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Joan Manuel Neyra QuijandríaU.S. Naval Medical Research Unit N° 6 - Lima, Lima, Peru.
Min LevineInfluenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
William CampbellAbt Associates, Inc, Atlanta, GA, USA.
Ran BalicerChief Physician's Office, Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel.
Mark G ThompsonInfluenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
SHIRI workgroup
Ben-Gurion University of the Negev · ILCenters for Disease Control and Prevention · USClalit Health Services · ILSchulman, Ronca & Bucuvalas · USUniversity of Michigan · USRabin Medical Center · ILSoroka Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI) prospectively follows a cohort of healthcare personnel (HCP) in two hospitals in Israel. SHIRI will describe the frequency of influenza virus infections among HCP, identify predictors of vaccine acceptance, examine how repeated influenza vaccination may modify immunogenicity, and evaluate influenza vaccine effectiveness in preventing influenza illness and missed work.

methodsCohort enrollment began in October, 2016; a second year of the study and a second wave of cohort enrollment began in June 2017. The study will run for at least 3 years and will follow approximately 2000 HCP (who are both employees and members of Clalit Health Services [CHS]) with routine direct patient contact. Eligible HCP are recruited using a stratified sampling strategy. After informed consent, participants complete a brief enrollment survey with questions about occupational responsibilities and knowledge, attitudes, and practices about influenza vaccines. Blood samples are collected at enrollment and at the end of influenza season; HCP who choose to be vaccinated contribute additional blood one month after vaccination. During the influenza season, participants receive twice-weekly short message service (SMS) messages asking them if they have acute respiratory illness or febrile illness (ARFI) symptoms. Ill participants receive follow-up SMS messages to confirm illness symptoms and duration and are asked to self-collect a nasal swab. Information on socio-economic characteristics, current and past medical conditions, medical care utilization and vaccination history is extracted from the CHS database. Information about missed work due to illness is obtained by self-report and from employee records. Respiratory specimens from self-collected nasal swabs are tested for influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, and coronaviruses using validated multiplex quantitative real-time reverse transcription polymerase chain reaction assays. The hemagglutination inhibition assay will be used to detect the presence of neutralizing influenza antibodies in serum. DISCUSSION: SHIRI will expand our knowledge of the burden of respiratory viral infections among HCP and the effectiveness of current and repeated annual influenza vaccination in preventing influenza illness, medical utilization, and missed workdays among HCP who are in direct contact with patients.

trial registrationNCT03331991 . Registered on November 6, 2017.

Indexed as

AbsenteeismAdultCohort StudiesFemaleHealth PersonnelHospitalsHumansInfluenza, HumanInfluenza VaccinesIsraelMaleMiddle AgedRespiratory Syncytial Virus, HumanRespiratory Tract InfectionsSurveys and QuestionnairesTreatment OutcomeInfluenza Vaccines

Identifiers

PMID30400834
PMCPMC6220521
OpenAlexW2900090965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.